Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Metformin for CV Complications in Diabetic Hypertension
NCT03253562Phase 4Completed
- Sponsor
- Modern University for Technology and Information
- Start
- Feb 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vildagliptin and metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Modern University for Technology and Information. Primary endpoints: benefit of reducing hypertension in diabetic hypertensive patients at 6 months, benefit of lowering cardiovascular risks for diabetic hypertensive patients at 6 months and 1 more. Started Feb 2017; status: completed.
02
Drugs
vildagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03253562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253562.